Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1371-1374

  Chantzichristos, Dimitrios ^a   Andréasson, Björn ^a   Johansson, Peter ^a  

^a UDDEVALLA HOSPITAL   (Sweden)

Author keywords

Bisphosphonates; Infusion time; Multiple myeloma; Pamidronate

Indexed keywords

PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE NECROSIS; CALCIUM BLOOD LEVEL; COMORBIDITY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPERTENSION; HYPOCALCEMIA; JAW DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTION; SIDE EFFECT; TREATMENT DURATION;

EID: 61549129356     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Berenson JR, Lichtenstein A, Porter L, et al. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med, 334:488-93.
2. Berenson JR, Rajdev L, Broder M. 2007. Bone complications in multiple myeloma. Cancer Biol Ther, 5: 1082-5.
3. de Lemos ML, Taylor SC, Barnett JB, et al. 2007. Renal safety of one hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database. J Oncol Pharm Prac, 12:193-9.
4. Desikan R, Veksler Y, Raza S, et al. 2002. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol, 119: 496-9.
5. Janssen van Doorn K, Neyns B, Van der Niepen P, et al. 2001. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron, 99:467-8.
6. Kanis JA, McCloskey EV, Taube T, et al. 1991. Rationale for the use of bisphosphonates in bone metastases. Bone, 12:13-8.
7. Kellihan MJ, Mangino PD. 1992 Pamidronate. Ann Pharmacother, 26:1262-9.
8. Kyle RA, Yee GC, Somerfield MR, et al. 2007. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol, 25:2464-72.
9. Lacy MQ, Dispenzieri A, Gertz MA, et al. 2006. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc, 81:1047-53.
10. Leyvraz S, Hess U, Flesch G, et al. 1992. Pharmacokinetics of pamidronate in patients with bone metastases. J Nat Cancer Inst, 84:78 8-92.
11. Lockridge L, Papac RJ, Perazella MA. 2002. Pamidronate-associated nephrotoxicity in a patient with Lagerhans's histiocytosis. Am J Kidney Dis, 40:E2.
12. Markowitz GS, Appel GB, Fine PL, et al. 2001. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephro, 12:1164-72.
13. Markowitz GS, Fine PL, D'Agati VD. 2002. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis, 39:1118-22.
14. Mehrotra B, Ruggiero S. 2006. Bisphosphonate complications including osteonecrosis of the jaw. Hematology, American Society of Hematology, Education Program Book, 356-60.
15. Migliorati CA, Siegel MA, Elting LS. 2006. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol, 7:508-14.
16. Nussbaum Sr, Younger J, Vandepol Cj, et al. 1993. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med, 95:297-304.
17. Rosen LS, Gordon D, Kaminski M, et al. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7:3 77-87.
18. Tanvetyanon T, Stiff PJ. 2006. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol, 17:6:897-907.
19. Tyrell CJ Collinson M, Madsen EL, et al. 1994. Intravenous pamidronate: infusion rate and safety. Ann Oncol, 5:27-29.
20. Yeh HS, Berenson JR. 2006. Treatment for myeloma bone disease. Clinical Cancer Research. 12:6279-84.